Time for a new dawn

In order to identify opportunities for cancer new product development, you have to be able to identify early emerging trends.

Coupled with this is uncovering the science capable of challenging current thinking or conventional wisdom, while providing a useful solution to what has been an intractable problem or better still, offers a technology solution, which previously did not exist.

With these issues in mind, in this post we’re taking a look at some recent developments in the fast moving field of targeted protein degradation (TPD), highlighting early data we think are not only noteworthy, but also offer potential for clinical impact down the road.

If you’re interested in protein degraders and molecular glues, you can find all our relevant content in this niche grouped here.

Want to know where the field may potentially be going? Then this post, and the next one are for you.

To continue reading our latest discussion on oncology new product development plus commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

Posted by